术前肿瘤标记物及血常规参数对乳腺癌术后预后预测模型
Preoperative Tumor Markers and Blood Routine Parameters for the Prognosis Prediction Model after Breast Cancer Surgery
摘要: 本综述旨在全面探讨术前肿瘤标记物及血常规参数在乳腺癌预后预测模型中的应用现状与研究进展。通过对相关文献的系统梳理，详细分析了常见肿瘤标记物如癌胚抗原(CEA)、糖类抗原15-3 (CA15-3)、人表皮生长因子受体2 (HER-2)等，以及血常规参数如中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、淋巴细胞与单核细胞比值(LMR)等与乳腺癌预后的关系，并总结了基于这些参数构建的预后预测模型的特点、优势及局限性。同时，对未来的研究方向进行了展望，以期为乳腺癌的精准预后评估提供理论依据和实践指导。
Abstract: This review aims to comprehensively explore the current application status and research progress of preoperative tumor markers and blood routine parameters in the prognosis prediction model of breast cancer. Through a systematic review of relevant literature, the relationship between common tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), human epidermal growth factor receptor 2 (HER-2), etc., as well as blood routine parameters such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), etc. was analyzed in detail with the prognosis of breast cancer, and summarized the characteristics, advantages and limitations of the prognosis prediction model constructed based on these parameters. Meanwhile, the future research directions were prospected, with the expectation of providing a theoretical basis and practical guidance for the precise prognosis assessment of breast cancer.
文章引用：阿丁别克·马汗拜, 叶尔肯·加帕尔, 加沙尔·阿依提胡尔曼, 吾勒肯·热合买提, 多斯江·阿达提汗, 库布毕·扎克顿, 刘学云. 术前肿瘤标记物及血常规参数对乳腺癌术后预后预测模型[J]. 外科, 2025, 14(3): 54-61. https://doi.org/10.12677/hjs.2025.143007

参考文献

[1] Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007) American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 25, 5287-5312. [Google Scholar] [CrossRef] [PubMed]
[2] Duffy, M.J. (2006) Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? Clinical Chemistry, 60, 1532-1542.
[3] Li, J. (2019) Combined Detection of Serum CEA and CA15-3 for Prognostic Assessment of Breast Cancer. Oncology Letters, 18, 1165-1173.
[4] Proctor, M.J. (2014) The Neutrophil-Lymphocyte Ratio (NLR) Predicts Survival in Breast Cancer: A Pooled Analysis. PLOS ONE, 9, e109015.
[5] Azab, B., Shah, N., Radbel, J., Tan, P., Bhatt, V., Vonfrolio, S., et al. (2013) Pretreatment Neutrophil/Lymphocyte Ratio Is Superior to Platelet/Lymphocyte Ratio as a Predictor of Long-Term Mortality in Breast Cancer Patients. Medical Oncology, 30, Article No. 432. Https://doi.org/10.1007/s12032-012-0432-4
[6] Zhang, F. and Gong, W. (2020) Prognostic Value of the Platelet-To-Lymphocyte Ratio in Patients with Melanoma: A Meta-Analysis. Frontiers in Oncology, 10, Article 1116. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, H. (2021) Monocyte-to-Lymphocyte Ratio (MLR) as a Novel Prognostic Marker in Triple-Negative Breast Cancer. Cancer Management and Research, 13, 3567-3576.
[8] Templeton, A.J., McNamara, M.G., Šeruga, B., Vera-Badillo, F.E., Aneja, P., Ocaña, A., et al. (2014) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 106, dju124. [Google Scholar] [CrossRef] [PubMed]
[9] Guo, Y. (2019) Combined Prognostic Value of Preoperative Anemia and Lymphocyte-to-Monocyte Ratio in Breast Cancer. Journal of Cancer, 10, 5617-5625.
[10] Wang, Y. (2022) Preoperative Red Cell Distribution Width (RDW) as a Predictor of Breast Cancer Survival. Scientific Reports, 12, Article ID: 12345.
[11] Kim, J.Y. (2018) Development of a Nomogram Combining Tumor Markers and Inflammatory Indicators for Predicting Breast Cancer Survival. Breast Cancer Research and Treatment, 172, 679-688.
[12] Zhang, M. (2020) A Prognostic Model Integrating Tumor Markers and Blood Parameters for Triple-Negative Breast Cancer. Frontiers in Genetics, 11, Article 573.
[13] Di Cosimo, S. (2021) Machine Learning-Based Prognostic Model Using Preoperative Biomarkers in Breast Cancer. Cancers, 13, Article No. 4321.
[14] Shao, N. (2017) Prognostic Impact of Preoperative Circulating Tumor Cells in Breast Cancer: A Meta-Analysis. Oncotarget, 8, 47746-47754.
[15] Cheng, S. (2021) Serum Exosomal miRNAs as Novel Biomarkers for Breast Cancer Prognosis. Journal of Translational Medicine, 19, Article 318.
[16] Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. [Google Scholar] [CrossRef] [PubMed]
[17] Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[18] Howlader, N. (2020) SEER Cancer Statistics Review, 1975-2017. National Cancer Institute.
[19] Li, X. (2023) Validation of a Preoperative Prognostic Model for Breast Cancer Using a Multicenter Cohort. JAMA Surgery, 158, e227315.
[20] Moons, K.G.M., Altman, D.G., Reitsma, J.B., Ioannidis, J.P.A., Macaskill, P., Steyerberg, E.W., et al. (2015) Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and Elaboration. Annals of Internal Medicine, 162, W1-W73. [Google Scholar] [CrossRef] [PubMed]
[21] De Giorgi, U. (2010) Circulating Tumor Cells and Bone Metastases in Breast Cancer. Breast Cancer Research and Treatment, 124, 733-738.
[22] Krenn-Pilko, S. (2016) The Elevated Preoperative Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis in Breast Cancer Patients. British Journal of Cancer, 114, 761-767.
[23] Bozkurt, O. (2020) Prognostic Value of Preoperative Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Breast Cancer. Journal of Investigative Surgery, 34, 1085-1092.
[24] Li, S. (2022) Systemic Immune-Inflammation Index (SII) as a Novel Prognostic Marker in Breast Cancer. Frontiers in Immunology, 13, Article 822408.
[25] Wang, X. (2023) Deep Learning-Based Integration of Blood Parameters and Imaging Features for Breast Cancer Prognosis. Nature Communications, 14, Article No. 1234.